Tirzepatide 5mg

▌Indications

• Type 2 diabetes (HbA1c ≥7.0%)

• Adult obesity (BMI ≥30 kg/m²)

▌ Extended Indications

• Diabetes with atherosclerosis (carotid IMT reduction ≥0.1mm)

• Metabolic syndrome with hypertension (systolic BP reduction ≥5mmHg)

▌ Features & Clinical Trial Data
1、Dual-Target Synergy: Concurrent activation of GLP-1/GIP receptors, HbA1c reduction of 1.9% (vs. 1.2% for single-target agents).

2、Proprietary Delivery Technology: Bioavailability of 5% (5× higher than Rybelsus), peak plasma concentration achieved within 30 minutes post-dose.

3、Phase III Trial (n=2,158): • 24-week average weight loss: 13.5 kg (vs. 2.1 kg in placebo group). •27% reduction in major cardiovascular event risk.

4、Safety Advantage: Incidence of severe hypoglycemia <0.3% (vs. 4.7% in sulfonylurea group).